Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
TECFIDERA® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.
American Society for Neurochemistry 46th Annual Meeting
Episode 54 with Dr. Jonathan Kipnis: Part 2 on meningeal lymphatic vessels in neuroinflammation, and clinical implications
Recruiting women smokers: the engineering of consent.
Episode 59 with Dr. Helmut Butzkueven on the new MS Brain Health initiative
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells.
Episode 45 with Dr. Simon Hametner on the role of iron in MS
Episode 58 with Dr. Gavin Giovannoni on the new MS Brain Health initiative
International Society for Neurovascular Disease (ISNVD)
FOCiS 2015 Meeting: Immunology by the Bay
SMC Says Yes to Aubagio® (teriflunomide), a New Once Daily First-line Oral Treatment Available for People with an Active Relapsing Remitting Form of MS
Episode 53: Part 1 with Dr. Jonathan Kipnis on the discovery of lymphatic vessels in the meninges
Scientists probe strategies to repair neuron damage in multiple sclerosis.
Gender as risk factor for autoimmune diseases.
Use of fumaric acid esters in psoriasis.
Episode 41 with Dr. Diego Cadavid on a clinical trial of anti-LINGO-1
National MS Society: Postdoctoral Fellowships
Improving the translational hit of experimental treatments in multiple sclerosis.
BIIB033 single ascending dose study in healthy volunteer subjects
Temporal trends in the incidence of multiple sclerosis: a systematic review.
12th International Society of Neuroimmunology Congress
Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis.
Parenteral Dilantin®
Postpartum disease activity and breastfeeding in multiple sclerosis revisited.
Pages
« first
‹ previous
…
47
48
49
50
51
52
53
54
55
…
next ›
last »
